Health Canada
Symbol of the Government of Canada

Common menu bar links

Drugs and Health Products

Consultation on the Prescription Drug List: Fluticasone propionate

Warning This content was archived on February 16, 2016.

Archived Content

Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after the date of archiving. Web pages that are archived on the Web are not subject to the Government of Canada Web Standards. As per the Communications Policy of the Government of Canada, you can request alternate formats on the "Contact Us" page.

Notice to the reader: The online consultation is now closed.

The purpose of this Notice of Consultation is to provide an opportunity to comment on the proposal to revise the listing for Adrenocortical Hormones or their salts or derivatives on the Human Prescription Drug List (PDL) to permit the non-prescription use of Fluticasone propionate for the conditions listed. Only the human part of the PDL is proposed to be revised.

A question-and-answer document has also been created to explain some of the changes to the new Prescription Drug List and the administrative process for assigning prescription status.

How to Get Involved

This consultation is open for comment until February 10, 2016. Please read through the information provided in the link below titled "Consultation Document".  Once read, please submit your comments via email, facsimile or by mail to:

Health Canada
Prescription Drug Status Committee
Address Locator 3102C3
Holland Cross, Tower B
1600 Scott Street
Ottawa, Ontario
K1A 0K9

Telephone: 613-957-1058
Facsimile: 613-941-1812
e-mail: drug_prescription_status-statut_d'ordonnance_des_drogues@hc-sc.gc.ca

Consultation Document

Interested parties are encouraged to provide comments and suggestions by February 10, 2016.

Reporting to Canadians

The results of the consultation will be made available on this website.

If you have any questions, contact us the Prescription Drug Status Committee.

Interested in our other consultations? Sign up and stay informed about topics that matter to you.